Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Daolin Tang, Guido Kroemer, Rui Kang
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 61

Showing 26-50 of 61 citing articles:

NPS‐2143 inhibit glioma progression by suppressing autophagy through mediating AKT–mTOR pathway
Jia‐Li Nie, Qi Li, Hai‐Tang Yin, et al.
Journal of Cellular and Molecular Medicine (2024) Vol. 28, Iss. 7
Open Access | Times Cited: 3
Cancer/Testis Antigens as Biomarker and Target for the Diagnosis, Prognosis, and Therapy of Lung Cancer
Ping Yang, Yingnan Qiao, Mei Meng, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 15
Therapeutic Potential of Intrabodies for Cancer Immunotherapy: Current Status and Future Directions
Thomas Böldicke
Antibodies (2022) Vol. 11, Iss. 3, pp. 49-49
Open Access | Times Cited: 15
Mutant Kras and mTOR crosstalk drives hepatocellular carcinoma development via PEG3/STAT3/BEX2 signaling
Yuandeng Luo, Xiaoyu Liu, Lei Fang, et al.
Theranostics (2022) Vol. 12, Iss. 18, pp. 7903-7919
Open Access | Times Cited: 14
Statins enhances antitumor effect of oxaliplatin in KRAS-mutated colorectal cancer cells and inhibits oxaliplatin-induced neuropathy
Masanobu Tsubaki, Tomoya Takeda, Takuya Matsuda, et al.
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 8
Reactivation of MAPK-SOX2 pathway confers ferroptosis sensitivity in KRASG12C inhibitor resistant tumors
K. Wang, Xin Zhang, Yufei Fan, et al.
Redox Biology (2024) Vol. 78, pp. 103419-103419
Open Access | Times Cited: 2
Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner
Christophe Bontoux, Véronique Hofman, Patrick Brest, et al.
Cancers (2022) Vol. 14, Iss. 7, pp. 1628-1628
Open Access | Times Cited: 12
Integrative analysis of cancer dependency data and comprehensive phosphoproteomics data revealed the EPHA2-PARD3 axis as a cancer vulnerability in KRAS-mutant colorectal cancer
Daigo Gunji, Ryohei Narumi, Satoshi Muraoka, et al.
Molecular Omics (2023) Vol. 19, Iss. 8, pp. 624-639
Open Access | Times Cited: 6
Design and Structural Optimization of Orally Bioavailable SOS1 Inhibitors for the Treatment of KRAS-Driven Carcinoma
Silong Zhang, Yu Zhang, Xin Chen, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 23, pp. 15856-15877
Closed Access | Times Cited: 9
The Nanotechnology-Based Approaches against Kirsten Rat Sarcoma-Mutated Cancers
Fernanda Andrade, Júlia German-Cortés, Sara Montero‐Herradón, et al.
Pharmaceutics (2023) Vol. 15, Iss. 6, pp. 1686-1686
Open Access | Times Cited: 5
Signalling in pancreatic cancer: from pathways to therapy
Kexun Zhou, Yingping Liu, Shiman Yuan, et al.
Journal of drug targeting (2023) Vol. 31, Iss. 10, pp. 1013-1026
Closed Access | Times Cited: 5
Deciphering the role of KRAS gene in oncogenesis: Focus on signaling pathways, genetic alterations in 3’UTR, KRAS specific miRNAs and therapeutic interventions
Yogita Chhichholiya, Harsh Vikram Singh, Rajesh Vashistha, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 194, pp. 104250-104250
Closed Access | Times Cited: 5
Reflections on drug resistance to KRAS inhibitors and gene silencing/editing tools for targeting mutant KRAS in cancer treatment
Zhaoyong Han, Ding Zhou, JiaMan Wang, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2022) Vol. 1877, Iss. 1, pp. 188677-188677
Closed Access | Times Cited: 8
Subgrouping testicular germ cell tumors based on immunotherapy and chemotherapy associated lncRNAs
Jian Cao, Zhizhong Liu, Junbin Yuan, et al.
Heliyon (2024) Vol. 10, Iss. 2, pp. e24320-e24320
Open Access | Times Cited: 1
The research advances in Kirsten rat sarcoma viral oncogene homolog (KRAS)-related cancer during 2013 to 2022: a scientometric analysis
Yujie Huang, Daitian Zheng, Zhongming Zhou, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Triple Blockade of Oncogenic RAS Signaling Using KRAS and MEK Inhibitors in Combination with Irradiation in Pancreatic Cancer
XUAN WANG, Judith Breuer, Stephan Garbe, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 6249-6249
Open Access | Times Cited: 1
Reprogramming Tumor-Associated Macrophages: The Role of MEK-STAT3 Inhibition in Lung Cancer
Sushama Rawat, Ehssan Moglad, Muhammad Afzal, et al.
Pathology - Research and Practice (2024) Vol. 265, pp. 155748-155748
Closed Access | Times Cited: 1
Synthetic Vulnerabilities in the KRAS Pathway
Marta Román, Elizabeth Hwang, E. Alejandro Sweet‐Cordero
Cancers (2022) Vol. 14, Iss. 12, pp. 2837-2837
Open Access | Times Cited: 6
Gain-of-Function Variomics and Multi-omics Network Biology for Precision Medicine
Mark M. Li, Sharad Awasthi, Sumanta Ghosh, et al.
Methods in molecular biology (2023), pp. 357-372
Closed Access | Times Cited: 2
Stratification of patients with KRAS-mutated advanced non-small cell lung cancer: improving prognostics
Yuda Zhang, Fanxu Zeng, Shixuan Peng, et al.
Expert Review of Respiratory Medicine (2023) Vol. 17, Iss. 9, pp. 743-751
Closed Access | Times Cited: 2
Dual roles of drug or its metabolite−protein conjugate: Cutting‐edge strategy of drug discovery using shotgun proteomics
Shilin Gong, Xiaolan Hu, Shengshuang Chen, et al.
Medicinal Research Reviews (2022) Vol. 42, Iss. 4, pp. 1704-1734
Closed Access | Times Cited: 4
KRAS Q61H Mutation Confers Cancer Cells with Acquired Resistance to SHP2 Inhibition
Yihui Song, Xinyu Yang, Bin Yu
Pharmaceutical Fronts (2022) Vol. 04, Iss. 01, pp. e40-e42
Open Access | Times Cited: 3
Small-molecule RAS/RAF Binding Inhibitors Allosterically Disrupt RAF Conformation and Exert Efficacy Against a Broad Spectrum of RAS-driven Cancers
Fumi Shima, Yoko Yoshikawa, Yoshiteru Makino, et al.
Research Square (Research Square) (2024)
Open Access
KRAS inhibitors in drug resistance and potential for combination therapy
Lala S. Rathod, Nikhil S. Sakle, Santosh N. Mokale
Tumori Journal (2024)
Closed Access
Covalent Inhibitors of MAP Kinases
Surya K. De
Drug design and discovery (2024), pp. 159-189
Closed Access

Scroll to top